To get the word out on AstraZeneca's needle-free FluMist Quadrivalent vaccine, the company has brought on James Van Der Beek--of "Dawson's Creek" fame--to participate in its "Insist on the Mist" campaign.
Ebola vaccine research is moving ahead at lightening speed thanks to combined public and private sector efforts, with GlaxoSmithKline unveiling fresh data showing that its experimental jab protected monkeys in a preclinical study.
A new breast cancer vaccine tested in a clinical trial at the University of Texas MD Anderson Cancer Center boosted survival rates in patients with elevated levels of a protein associated with cancer growth, a new study shows.
The new nod could boost sales of the French drugmaker's vaccine, a lift it could use after Menactra's top-line haul in 2013 sank to €424 million in a 21.5% slide.
Sanofi's dengue vaccine isn't slated to hit the market until late next year, pending approval, but it already has some competition on the horizon. Takeda has its eye on nods in the U.S. and Europe for its own candidate by the 2017-18 fiscal year, it says.
Two lawsuits claiming Merck lied about the efficacy of its mumps vaccine won't be going away anytime soon. A federal judge in Pennsylvania refused to dismiss the suits, filed by a pair of whistleblowers and a group of doctors and payers, and now, they're on their way to trial.
GlaxoSmithKline's Canadian flu vaccine plant has been in the spotlight recently for problems that spurred an FDA warning letter and a talking-to from Health Canada. But it's different problems that the British drugmaker now says will keep it from filling about 30% of its Canadian order for this season--and they could compromise some of its U.S. shipments, too.
Another Big Pharma player is joining the hustle toward an Ebola vaccine as the death toll surpasses 1,900 victims, eclipsing the total number of people who died from the disease in all previous outbreaks combined.
Looking back on data from old pediatric HIV vaccine trials, researchers have found that two vaccines studied in the 1990s elicited a specific antibody response that was unknown at the time to be associated with HIV protection.
Results from Sanofi's dengue vaccine trial are in, and once again, the data confirm its overall efficacy. But notably, this trial also saw an improvement in protection against dengue serotype 2, a viral strain that's tripped up the vaccine in previous studies.
After initially leaving Novartis' meningitis B jab, Bexsero, off its national immunization program, the British government is now negotiating with the Swiss pharma over price--a series of events that's led a top Novartis Vaccines employee to tab the U.K. vaccination assessment system "flawed."
Back in June, Amgen said it was eyeing a U.S. application for its cancer-fighting viral vaccine in the short term but would be looking outside the U.S. as well. After submitting its candidate to the FDA in July, the company now says it's turned over a marketing authorization application to the European Medicines Agency for the melanoma candidate.
Look out, Sanofi. Pfizer's Clostridium difficile candidate has just nabbed an FDA fast-track designation that should help it pick up some ground in the race to bring the first vaccine for the disease to market.
Though polio has been nearly eradicated from the globe, researchers have made a troubling discovery that underscores the need to boost vaccination rates in countries that have seen recent outbreaks as well as develop new, more potent vaccines.
Just over a month after striking an immunotherapy pact with AstraZeneca, New Jersey biotech Advaxis is back with another Big Pharma agreement. This time, the company will be teaming up with Merck to test its cancer vaccine, ADXS-PSA, in combination with the latter's checkpoint inhibitor pembrolizumab.
As the Ebola outbreak continues to claim victims in West Africa, governments and industry alike are racing toward a therapeutic or preventive drug that could help halt its deadly spread and avert future human crises involving the virus.
Earlier this year, when Pfizer made a play for rival pharma giant AstraZeneca, CEO Ian Read listed the British drugmaker's vaccines portfolio as a motivating factor. Now, rumors are swirling that the company could be eyeing Actavis as a backup plan. On the one hand, the New Jersey generics maker lacks vaccines offerings. And on the other, with the recent developments affecting Pfizer's unit, how much does that matter?
There's a big patient pool waiting out there for any diabetes vaccine maker that can bring a product to market, but so far, it's been a rocky road. Diamyd Medical is among the companies that have seen their share of setbacks. But after a Phase III stumble back in 2011, the EU is putting forth some cash to test its vaccine in an ongoing combination study.
Frederick, MD-based Vaccinogen has scored $10 million to fund work on its colon cancer candidate, OncoVax.
As the U.S. continues to experience the highest number of measles cases this year since the highly contagious viral illness was eliminated nationwide in 2000, health officials and researchers are looking for ways to keep vaccination rates in check.